CureVac N.V. (CVAC)
Automate Your Wheel Strategy on CVAC
With Tiblio's Option Bot, you can configure your own wheel strategy including CVAC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVAC
- Rev/Share 2.3855
- Book/Share 3.1051
- PB 1.5336
- Debt/Equity 0.0559
- CurrentRatio 7.2761
- ROIC 0.2052
- MktCap 1072198726.056
- FreeCF/Share 0.3733
- PFCF 12.8016
- PE 6.5871
- Debt/Assets 0.0485
- DivYield 0
- ROE 0.289
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CVAC | Jefferies | Buy | Hold | -- | $5 | June 13, 2025 |
News
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
Read More
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ: CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, …
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Read More
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
Published: June 12, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.
Read More
CureVac Stock Soars on BioNTech Buyout
Published: June 12, 2025 by: Schaeffers Research
Sentiment: Positive
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
Read More
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
Published: June 12, 2025 by: Proactive Investors
Sentiment: Positive
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.
Read More
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Published: April 10, 2025 by: Seeking Alpha
Sentiment: Neutral
CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Scientific Officer Axel Sven Malkomes - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Ryan McElroy - Leerink Partners Roger Song - Jefferies Jasmine Fels - UBS Roy Buchanan - Citizens JMP Jonathan Miller - Evercore ISI Chiara Montironi - Kempen Operator Greetings.
Read More
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
Published: March 28, 2025 by: Benzinga
Sentiment: Positive
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
Read More
About CureVac N.V. (CVAC)
- IPO Date 2020-08-14
- Website https://www.curevac.com
- Industry Biotechnology
- CEO Dr. Alexander Zehnder M.B.A., M.D.
- Employees 825